Prosecution Insights
Last updated: April 19, 2026
Application No. 18/668,678

ALLOSTERIC INHIBITOR OF WEE1 KINASE

Non-Final OA §102
Filed
May 20, 2024
Examiner
ANDERSON, REBECCA L
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
H. Lee Moffitt Cancer Center and Research Institute, Inc.
OA Round
3 (Non-Final)
73%
Grant Probability
Favorable
3-4
OA Rounds
2y 5m
To Grant
97%
With Interview

Examiner Intelligence

Grants 73% — above average
73%
Career Allow Rate
749 granted / 1022 resolved
+13.3% vs TC avg
Strong +24% interview lift
Without
With
+24.0%
Interview Lift
resolved cases with interview
Typical timeline
2y 5m
Avg Prosecution
44 currently pending
Career history
1066
Total Applications
across all art units

Statute-Specific Performance

§101
0.6%
-39.4% vs TC avg
§103
17.0%
-23.0% vs TC avg
§102
25.0%
-15.0% vs TC avg
§112
31.8%
-8.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1022 resolved cases

Office Action

§102
DETAILED ACTION Claims 1-4 are currently pending in the instant application. Claim 1 is rejected. Claims 2-4 are withdrawn from consideration as being for non-elected subject matter. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 29 December 2025 has been entered. Election/Restrictions Applicant’s election without traverse of Group I and the species: PNG media_image1.png 94 312 media_image1.png Greyscale in the reply filed on 25 February 2025 has been previously acknowledged. According to MPEP 803.02, the examiner has previously determined whether the elected species is allowable. Applicants’ elected species appears allowable. As applicant has amended claim 1 to overcome the 35 USC 102(a)(1) rejection as being anticipated by US Patent No. 4,511,709, the examiner has now extended the search and examination according to MPEP 803.02 to the compound PNG media_image2.png 126 260 media_image2.png Greyscale which is not allowable. Claim 1 has been examined to the extent that it is readable on the elected embodiment, the elected species and the above mentioned compound. Response to Amendment and Remarks Applicant's amendment and remarks filed 29 December 2025 have been fully considered and entered into the instant application. Applicant’s amendment to delete the compound PNG media_image3.png 122 288 media_image3.png Greyscale has overcome the 35 USC 102(a)(1) rejection as being anticipated by US Patent No. 4,511,709. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Sarkar et al. Journal of Applied Polymer Science, Vol. 105, 1793-1801 (2007). Sarkar et al. discloses the compound H-DA on page 1796, Scheme 1: PNG media_image4.png 146 774 media_image4.png Greyscale wherein R is H. This compound is: PNG media_image5.png 134 422 media_image5.png Greyscale which corresponds to and anticipates the second listed compound of claim 1 which is formula PNG media_image2.png 126 260 media_image2.png Greyscale . Therefore, claim 1 is anticipated. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to REBECCA L ANDERSON whose telephone number is (571)272-0696. The examiner can normally be reached Monday-Friday from 6am-2pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew Kosar can be reached at 571-272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /REBECCA L ANDERSON/Primary Examiner, Art Unit 1626 ____________________ 7 January 2026 Rebecca Anderson Primary Examiner Art Unit 1626, Group 1620 Technology Center 1600
Read full office action

Prosecution Timeline

May 20, 2024
Application Filed
Mar 04, 2025
Non-Final Rejection — §102
Jul 07, 2025
Response Filed
Jul 24, 2025
Final Rejection — §102
Dec 29, 2025
Request for Continued Examination
Jan 06, 2026
Response after Non-Final Action
Jan 07, 2026
Non-Final Rejection — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12582645
Chemokine CXCR4 Receptor Modulators and Uses Related Thereto
2y 5m to grant Granted Mar 24, 2026
Patent 12570666
FUROINDAZOLE DERIVATIVES
2y 5m to grant Granted Mar 10, 2026
Patent 12565504
SPIROCYCLIC O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS
2y 5m to grant Granted Mar 03, 2026
Patent 12545649
WDR5-MYC INHIBITORS
2y 5m to grant Granted Feb 10, 2026
Patent 12540141
NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS
2y 5m to grant Granted Feb 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
73%
Grant Probability
97%
With Interview (+24.0%)
2y 5m
Median Time to Grant
High
PTA Risk
Based on 1022 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month